Telestroke involves using telemedicine technologies to connect stroke specialists, often neurologists, with patients in remote or rural hospitals that don't have in-house stroke expertise. Through real-time, live audio and visual connections, the specialist can assess the patient, determine if they're having a stroke, and recommend the best treatment. This remote evaluation aims to expedite the treatment decision-making process so patients can receive potentially life-saving therapies like thrombolysis medications or endovascular procedures as quickly as possible.
History of Telestroke Services
The first formal telestroke programs emerged in the late 1990s and early 2000s as telemedicine technologies advanced enough to enable high-quality video interactions between clinicians. Early pilot studies demonstrated telestroke could assess stroke patients just as accurately as in-person evaluations. As evidence grew of its benefits, more stroke centers and community hospitals partnered to create formal telestroke networks across regions and states. Today, telestroke programs exist nationwide, connected by secure telemedicine carts, desktop apps, and mobile technologies that allow specialists to cover a wide geographic area remotely.
Benefits for Patients
Access to 24/7 specialist expertise. Telestroke Services allows community hospitals without on-site stroke specialists round-the-clock access to neurologists and other experts. This improves patients' chances of rapid diagnosis and treatment initiation even outside normal business hours.
Reduced time to treatment. Numerous studies show telestroke can significantly decrease the time between symptom onset and initiation of clot-busting medications like tissue plasminogen activator (tPA). Faster treatment correlates to better outcomes.
Expanded eligibility for therapies. By enabling remote specialist consultations, telestroke elevates the standard of care for stroke patients even in smaller, rural hospitals. More patients may qualify for advanced treatments previously only available at large stroke centers.
Improved post-stroke outcomes. Meta-analyses reveal telestroke patients have higher rates of independent ambulation at discharge and lower in-hospital mortality compared to similar stroke cases without remote specialist input. Faster treatment times likely drive these improved outcomes.
Benefits for Hospitals
Around-the-clock access to expertise. Community hospitals gain neurology expertise 24/7 without requiring in-house staffing. This improves hospitals' capacity to treat strokes and reduces risk of complications.
Increased patient volume. By adding stroke consultation services, telestroke networks help rural hospitals remain full-service providers for their regions rather than transferring all complex cases. This boosts patient loyalty and financial viability.
Quality improvement support. Dedicated telestroke neurologists mentor staff at community hospitals on the latest stroke treatment protocols and guidelines. This enhances the overall level of stroke care systemwide.
Equipment and Workflow Considerations
Hardware requirements. At minimum, hospitals need high-quality video cameras, microphones, and screens on moveable carts or built into examination rooms to enable face-to-face telemedicine visits. Sufficient bandwidth is also critical.
User training. All clinicians involved in telestroke—from nurses to physicians—require education on properly operating the equipment and optimizing clinical workflows with remote technology. Comfort with the tool is important for maximizing benefits.
Standardized documentation. Clear processes and templated notes help streamline documentation between sites to maintain compliance and care coordination post-visit.
Privacy and security. Protecting patient information transmitted during telestroke encounters requires robust data safeguards like encrypted transmissions, password protections, and other privacy measures.
Supporting Research on Telestroke Outcomes
Continued research is still needed to refine telestroke programs and fully understand their long-term impacts. Key areas investigators continue exploring include:
- Long-term post-stroke functional outcomes like ability to perform daily living activities independently at 3, 6, and 12 months post-event. While in-hospital outcomes seem positive, long-term effects require more study.
- Regional differences in utilization patterns and whether telestroke has maximized penetration in all communities that could benefit, especially very rural areas. Targeted interventions may be needed.
- Cost-effectiveness analyses to solidify return on investment for telestroke networks' upfront hardware and training budgets. Strong data could drive increased adoption.
- Adapting telestroke models for acute stroke care in the home or via mobile health technologies. As telemedicine expands, new use cases may emerge.
- Optimization of multispecialty telemedicine programs involving neurology, but also neurosurgery, cardiology and other specialists stroke patients frequently intersect with.
As telemedicine technologies continue advancing, telestroke programs will undoubtedly grow more sophisticated to benefit even greater numbers of stroke victims. Ongoing research aims to unlock telestroke's full potential to transform stroke care delivery across diverse communities. With ongoing optimization, telestroke services may become the standard of care for rapid stroke treatment everywhere.
Get more insights on Telestroke Services
Ischemic stroke market research report: by diagnosis (CT, MRI, carotid ultrasound, cerebral angiography), drug class (tissue plasminogen activator, anticoagulant, antiplatelet, antihypertensive), surgery, end user – Global forecast till 2023Market Scenario:Ischemic strokes occur as a result of an obstruction within a blood vessel supplying blood to the brain.
The underlying condition of this type of obstruction is the development of fat deposits lining the vessel walls, which is known as atherosclerosis.
According to the World Health Organization (WHO), stroke accounts for around 17 million deaths annually.
As per the Centers for Disease Control and Prevention (CDC), stroke leads to 1 out of every 20 deaths costing around USD 34 billion each year in the U.S. Higher rates of mortality associated with strokes highlight an impending need for innovative drugs and diagnostic devices.Avail a Free Sample Insights @ https://www.marketresearchfuture.com/sample_request/5423 The global market for ischemic stroke is expected to grow at a CAGR of approximately 8.3% during the forecast period 2017-2023.Some of key the players in the Americas ischemic stroke market are Abbott Laboratories (U.S.), Medtronic plc (U.S.), Boston Scientific Corporation (U.S.), Cordis Corporation (U.S.), Koninklijke Philips N.V. (Netherland), GE Healthcare (U.S.), Stryker Corporation (U.S.), Genentech, Inc. (U.S.), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Boehringer Ingelheim (Germany), Sanofi (France), Covidien plc (Ireland), Philips Healthcare (U.S.), Johnson & Johnson (U.S.), Penumbra, Inc. (U.S.), GE Healthcare (U.S.), Siemens Healthcare (U.S.), Hitachi, Ltd (Japan), Biogen (U.S.), Daiichi Sankyo (U.S.), Pfizer Inc. (U.S.), and othersSegmentation:The ischemic stroke is segmented on the basis of diagnosis, drug class, surgery and end-users.On the basis of the diagnosis, the market is segmented into Computed Tomography (CT), Magnetic resonance imaging (MRI), carotid ultrasound, cerebral angiography, electrocardiography, echocardiography, and others.On the basis of the drug class, the market is segmented into tissue plasminogen activator, anticoagulant, antiplatelet, antihypertensive, and othersOn the basis of the surgery, the market is segmented into carotid endarterectomy, angioplasty, and endovascular mechanical thrombectomyOn the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.Browse Complete Premium Research Report@ https://www.marketresearchfuture.com/reports/ischemic-stroke-market-5423 Intended Audience:Ischemic Stroke Drug SuppliersIschemic Stroke Drug ManufacturersResearch and Development (R) CompaniesMedical Research LaboratoriesAcademic Medical Institutes and UniversitiesAbout Market Research Future:At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.Contact:Market Research Future +1 646 845 9312Email: [email protected]
- Cerebrolysin 10 x 2 ml- Cerebrolysin 5 x 5 ml- Cerebrolysin 5 x 10 ml Cerebrolysin is a neurometabolic stimulator based on neuropeptides (20 percent) and amino acids (80 percent) isolated from pig brain tissue.
It was developed in 1949 by Gerhart Harrer, an Austrian professor, and approved on August 1, 1954.
Used as a treatment for: - Strokes and complications associated with strokes- Depression, anxiety, and other brain diseases- Alzheimer's disease and other types of dementia- Traumatic brain injury and spinal cord injuries- ADHD in children Country of Manufacture: Austria Contraindications– individual intolerance to the drug– acute renal failure– status epilepticus Side effects– fever, sensation of heat (with rapid intravenous infusion)Rarely:– headache, dizziness– loss of appetite, nausea, vomiting, dyspepsia, diarrhea, constipation– allergic reactions: skin redness, itching and burning at the injection site Mode of applicationIt is used only parenterally: in the form of intramuscular injections (up to 5 ml), and intravenous infusions (10-60 ml), it is recommended to enter only by slow intravenous infusions after dilution with the proposed standard solutions for infusion.
Doses and duration of treatment depend on the nature and severity of the disease, as well as on the patient’s age.
The standard duration of treatment is 4 weeks (5 injections / infusions per week, preferably daily).To increase the effectiveness of treatment, repeated courses can be carried out until positive treatment results are obtained.
After the first course, the frequency of prescribing doses can be reduced to 2 or 3 times a week.In Alzheimer’s disease, dementia syndrome of various origins: intravenous infusion of 20-30 ml in 100-200 ml of saline, for a course of treatment 20 infusions, 5 infusions per week (followed by a 2-day break) for 28 days.
